AZ's asthma candidate misses again in Phase III

AstraZeneca plc (LSE:AZN; NYSE:AZN) said tralokinumab (CAT-354) missed the primary endpoint in both the Phase III STRATOS 2 and TROPOS trials to treat severe uncontrolled asthma. The pharma could not be reached for next steps for the program.

On the primary endpoint of STRATOS 2, tralokinumab failed to significantly reduce annual asthma exacerbation rate in patients with elevated levels of fractional exhaled nitric oxide (FeNO) vs. placebo. On the primary endpoint of TROPOS, tralokinumab failed to significantly reduce oral corticosteroid use vs. placebo...